Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Business Update and Directorate Change
-
Denison Mines (DNN) Announces Proposed 25M Common Offering at $0.20/Sh
-
Denison Announces US$5 Million Public Offering
-
Exagen (XGN) PT Lowered to $19 at Cantor Fitzgerald
-
Denison Announces Overnight Marketed Offering
-
Alexco Resource (AXU) Announces 4.054M Common Share Offering
-
Alexco Announces $7.5 Million Common Share Public Offering
-
Curaleaf Holdings Inc. (CURA:CN) (CURLF) PT Lowered to $4.10 at Cantor Fitzgerald
-
SDX Energy PLC Announces Implications of FCA Announcement of 21 March 2020
-
Cantor Fitzgerald Starts Grid Dynamics Holdings (GDYN) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on Pfizer (PFE)
-
ORCHID ISLAND CAPITAL ANNOUNCES MARCH 2020 MONTHLY DIVIDEND AND FEBRUARY 29, 2020 RMBS PORTFOLIO CHARACTERISTICS
-
Aesthetic Medical Intl. (AIH) PT Lowered to $12 at Cantor Fitzgerald
-
Medical Resource Acquisition Group, LLC is Focused on Replacing Rockwell Medical Directors to Balance the Board, Improve Governance and Bring Much-Needed Transparency to RMTI Shareholders
-
Rockwell Medical (RMTI) Announces $35 Million Debt Financing Agreement with Innovatus Capital Partners, LLC
-
Rockwell Medical, Inc. Announces $35 Million Debt Financing Agreement with Innovatus Capital Partners, LLC
-
Energy Fuels Announces 2019 Results
-
Tilray (TLRY) PT Lowered to $4.90 at Cantor Fitzgerald
-
Prophotonix Limited Announces Statement Re Grant Award
-
UPDATE: Cantor Fitzgerald Upgrades CymaBay Therapeutic (CBAY) to Overweight
-
Cantor Fitzgerald Starts Hutchison China MediTech Ltd. (HCM) at Overweight
-
Freddie Mac Prices $865 Million Multifamily K-Deal, K-F76
-
Cerner (CERN) PT Lowered to $83 at Cantor Fitzgerald
-
SDX Energy PLC Announces Result of Rabul-3 Well, West Gharib, Egypt
-
UPDATE: Aurinia Pharmaceuticals (AUPH) PT Raised to $32 at Cantor Fitzgerald; Not Just a Takeout Play
-
Grid Dynamics Goes Public through Business Combination with ChaSerg Technology Acquisition Corp.
-
Investors fret over risks to U.S. corporate credit as coronavirus spreads
-
Optinose (OPTN) PT Lowered to $21 at Cantor Fitzgerald
-
Form X-17A-5 CANTOR FITZGERALD & CO. For: Dec 31
-
Health Insurance Innovations (HIIQ) Sell-Off 'Overone' - Cantor Fitzgerald
-
SymphonyAI Group Acquires Healthcare Imaging AI Technology Leader TeraRecon
-
Aridis Pharmaceuticals Provides Update on Investor Day Featuring Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
-
SDX Energy PLC Announces Update on drilling operations in Morocco and Egypt
-
Cantor Fitzgerald Starts ZIOPHARM Oncology (ZIOP) at Overweight
-
Tilray (TLRY) PT Lowered to $17.50 at Cantor Fitzgerald Even After Drop There is Room for Disappointment
-
Form X-17A-5 CANTOR FITZGERALD & CO. For: Dec 31
-
Avalon Adds Five Senior Hires to Event Driven and International Equities Teams
-
Mereo BioPharma (MREO) Reports Positive Feedback from Type B End-of-Ph. 2 Meeting with FDA & Outlines Pivotal Ph. 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
-
Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
-
Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
-
Mustang Bio (MBIO) Weakness Creates 'Clear' Buying Chance - Cantor Fitzgerald
-
Freddie Mac Prices $580 Million Multifamily K-Deal, K-HG2, Backed by Properties Controlled by Harbor Group International, LLC
-
UPDATE: Cantor Fitzgerald Starts Anavex Life Sciences (AVXL) at Overweight
-
Freddie Mac Prices $870 Million Multifamily K-Deal, K-F75
-
Momenta Pharmaceuticals (MNTA) PT Raised to $30 at Cantor Fitzgerald
-
Pagaya Closes $200 Million Consumer Credit ABS
-
Castlight Health Inc. (CSLT) PT Lowered to $2 at Cantor Fitzgerald Following Earnings
-
Evolent Health (EVH) PT Lowered to $14 at Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Starts Arcutis Biotherapeutics Inc. (ARQT) at Overweight
-
UPDATE: Cantor Fitzgerald Downgrades Galapagos NV (GLPG:NA) (GLPG) to Neutral

